ADMA (ADMA Biologics) Moat Score: 5/10 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
68 GF Score
Price $8.28
GF Value $18.16
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Moat Score?

ADMA Biologics ADMA -1.19% 68 Moat Score is 5 as of Jul. 25, 2026. GuruFocus rates ADMA with a GF Score™ of 68/100 and a GF Value™ of $18.16 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, ADMA Biologics ranks better than 96.7% on this metric.

ADMA Biologics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

ADMA Biologics has Narrow Moat: ADMA Biologics Inc has a solid narrow moat due to its proprietary technology and focus on niche biologics. The company benefits from some regulatory barriers and intellectual property, but lacks strong market leadership and brand strength to warrant a wide moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ADMA Biologics might have Narrow Moat - Solid narrow moat.

ADMA Biologics  (NAS:ADMA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ADMA Biologics Moat Score Related Terms

ADMA vs ZLAB, HRMY, STOK: Moat Score Comparison

For the Biotechnology subindustry, ADMA Biologics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ADMA Biologics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Moat Score distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Moat Score falls into.


ADMA
68GF Score
ADMA Biologics Inc ADMA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
ADMA Biologics (ADMA) has a Moat Score of 5 as of Jul. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, ADMA Biologics ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is ADMA Biologics' Moat Score too high?
ADMA Biologics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. ADMA Biologics' value of 5 is 150% above this industry median. Based on the distribution chart, ADMA Biologics ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Moat Score compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #46 out of 1396 companies for Moat Score. This places ADMA Biologics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. ADMA Biologics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.16, compared to a current price of $8.28 — trading 54.4% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Moat Score is 5 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.28 is trading 54.4% below its estimated GF Value™ of $18.16. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Moat Score: 5
  • GF Value™: $18.16 vs. price of $8.28 (54.4% below fair value)
  • GF Score™: 68/100 with 2 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1396)

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score

Get the complete analysis for ADMA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.28
Price
$18.16
GF Value